Your browser doesn't support javascript.
loading
Polycomb EZH1 regulates cell cycle/5-fluorouracil sensitivity of neuroblastoma cells in concert with MYCN.
Shinno, Yoshitaka; Takenobu, Hisanori; Sugino, Ryuichi P; Endo, Yuki; Okada, Ryu; Haruta, Masayuki; Satoh, Shunpei; Mukae, Kyosuke; Shaliman, Dilibaerguli; Wada, Tomoko; Akter, Jesmin; Ando, Kiyohiro; Nakazawa, Atsuko; Yoshida, Hideo; Ohira, Miki; Hishiki, Tomoro; Kamijo, Takehiko.
Afiliação
  • Shinno Y; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Takenobu H; Department of Pediatric Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Sugino RP; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Endo Y; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Okada R; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Haruta M; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Satoh S; Laboratory of Tumor Molecular Biology, Department of Graduate School of Science and Engineering, Saitama University, Saitama, Japan.
  • Mukae K; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Shaliman D; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Wada T; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Akter J; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Ando K; Laboratory of Tumor Molecular Biology, Department of Graduate School of Science and Engineering, Saitama University, Saitama, Japan.
  • Nakazawa A; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Yoshida H; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Ohira M; Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
  • Hishiki T; Department of Clinical Research, Saitama Children's Medical Center, Saitama, Japan.
  • Kamijo T; Department of Pediatric Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Cancer Sci ; 113(12): 4193-4206, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36052716
ABSTRACT
In the present study, we found that EZH1 depletion in MYCN-amplified neuroblastoma cells resulted in significant cell death as well as xenograft inhibition. EZH1 depletion decreased the level of H3K27me1; the interaction and protein stabilization of MYCN and EZH1 appear to play roles in epigenetic transcriptional regulation. Transcriptome analysis of EZH1-depleted cells resulted in downregulation of the cell cycle progression-related pathway. In particular, Gene Set Enrichment Analysis revealed downregulation of reactome E2F-mediated regulation of DNA replication along with key genes of this process, TYMS, POLA2, and CCNA1. TYMS and POLA2 were transcriptionally activated by MYCN and EZH1-related epigenetic modification. Treatment with the EZH1/2 inhibitor UNC1999 also induced cell death, decreased H3K27 methylation, and reduced the levels of TYMS in neuroblastoma cells. Previous reports indicated neuroblastoma cells are resistant to 5-fluorouracil (5-FU) and TYMS (encoding thymidylate synthetase) has been considered the primary site of action for folate analogues. Intriguingly, UNC1999 treatment significantly sensitized MYCN-amplified neuroblastoma cells to 5-FU treatment, suggesting that EZH inhibition could be an effective strategy for development of a new epigenetic treatment for neuroblastoma.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Complexo Repressor Polycomb 2 / Neuroblastoma Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Complexo Repressor Polycomb 2 / Neuroblastoma Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article